{
    "clinical_study": {
        "@rank": "98979", 
        "arm_group": {
            "arm_group_label": "Recombine Endostatin", 
            "arm_group_type": "Experimental", 
            "description": "Induction chemotherapy:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles Synchronous chemotherapy: cisplatin 80 mg/m2 points d1-2, 21days for a cycle, 2 cycles, the same day in radiation therapy. Synchronous chemotherapy in chemotherapy day one recombinant human vascular endothelial inhibin 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment"
        }, 
        "brief_summary": {
            "textblock": "1) Observe and compare the curative effect of endostatin/recombined Endostatin in alliance\n      with neoadjuvant chemotherapy and Concurrent chemo-radio therapy to treat the local advanced\n      nasopharyngeal darcinoma; 2) Evaluate the security and tolerability in endostatin/recombined\n      Endostatin in alliance with neoadjuvant chemotherapy and Concurrent chemo-radio therapy to\n      treat the local advanced nasopharyngeal darcinoma."
        }, 
        "brief_title": "Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "1\u3001Enough Cases", 
            "2\u3001Elekta Precise 1343 Digital Control Electron Linear Accelerator", 
            "Can Undertake Nasopharyngeal Carcinoma Specimens in the Materia\uff0c", 
            "Image Department of Nose Pharynx Ministry MRI Dynamic Testing,"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "1. experimental group:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human\n           endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles;followed\n           by concurrent chemoradiation(Cisplatin 80mg/m2 iv in day 1,21 +human endostatin\n           7.5mg/m2 iv in day 1-14 and Concurrent Intensity-modulated radiation therapy)\n\n        2. Control group:group:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1  and\n           three weeks repeat and total two cycles;followed by concurrent chemoradiation(Cisplatin\n           80mg/m2 iv in day 1,21 and Concurrent Intensity-modulated radiation therapy)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Voluntary and sign the informed consent form; 2) Age 18-70 years old, male or female;\n             3) histologically proved to be keratinizing carcinoma or non-keratinizing carcinoma;\n             4) nasopharyngeal darcinoma 2010 UICC staging III-IV A, IV B; 5) measurable Primary\n             tumors; 6) karnofsky score\u226570; ECOG\u22652; 7) Expected survival\u22656 months; 8) Women in\n             productive age should guarantee use contraceptives during study period; 9)\n             Hemoglobin(HGB) \u2265100g/L, white blood cell(WBC) \u22654\u00d7109 /L\uff0cPlatelet\uff08PLT\uff09\u2265100\u00d7109 /L.\uff08or\n             white blood cell and platelet not less than our hospital's Normal lowest index\uff09; 10)\n             liver function: Alanine amino transferase (ALAT), aspartate aminotransferase (ASAT)\n             <1.5 times the upper limit of the normal index; total bilirubin<1.5\u00d7ULN; 11) liver\n             function: serum creatinine<1.5\u00d7ULN; 12) do not have severe complication, such as\n             Hypertensio, Diabetes and History of mental illness; 13) this treatment is First\n             treatment process (do not have a H&N Radiation history; do not have a history of\n             Concurrent chemoradiotherapy; do not have chemotherapy history in 3 months.\n\n        Exclusion Criteria:\n\n          1. Have a distant metastasis; 2) The primary focal tumors or lymph node already had a\n             surgical treatment (except for biopsy); 3) Already had a radiotherapy for primary\n             focal or lymph node; 4) Patient who received the the epidermal growth factor targeted\n             therapy; 5) The primary focal had received chemoradiotherapy or immunotherapy; 6)\n             Patient who suffered from other malignant tumor (except for cured basal cell\n             carcinoma or carcinoma in situ of cervix); 7) Subject who have taken other drug test\n             in 1 month; 8) Peripheral Neuropathy> level; 9) pregnant woman or Lactating Women and\n             Women in productive age who refuse take contraception in observation period; 10)\n             subject with a severe allergic history or idiosyncratic; 11) subject with severe\n             pulmonary and cardiopathic disease history; 12) refuse or incapable to sign the\n             informed consent form of participating this trial; 13) drug abuse or alcohol\n             addicted; 14) subject with a Personality or psychiatric diseases, people with no\n             legal capacity or people with limited capacity for civil conduct."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689558", 
            "org_study_id": "20111220"
        }, 
        "intervention": {
            "arm_group_label": "Recombine Endostatin", 
            "description": "Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment", 
            "intervention_name": "Recombine Endostatin", 
            "intervention_type": "Drug", 
            "other_name": "recombinant human vascular endothelial inhibin"
        }, 
        "intervention_browse": {
            "mesh_term": "Endostatins"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "nasopharynx cancer,Image department of nose pharynx ministry", 
        "lastchanged_date": "March 11, 2013", 
        "location": {
            "contact": {
                "email": "jinf8865@gmail.com", 
                "last_name": "Feng Jin, Professor", 
                "phone": "+86 13985124806"
            }, 
            "facility": {
                "address": {
                    "city": "Guiyang", 
                    "country": "China", 
                    "state": "Guizhou", 
                    "zip": "550002"
                }, 
                "name": "Cancer Hospital of Guizhou province"
            }, 
            "investigator": {
                "last_name": "Feng Jin, Professor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma", 
        "overall_contact": {
            "email": "jinf8865@gmail.com", 
            "last_name": "Feng Jin, Professor", 
            "phone": "+86 13985124806"
        }, 
        "overall_official": {
            "affiliation": "Cancer Hospital of Guizhou Province", 
            "last_name": "Jin Feng, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "observe and compare the curative effect of endostatin/recombined Endostatin in alliance with neoadjuvant chemotherapy and Concurrent chemo-radio therapy to treat the local advanced nasopharyngeal darcinoma\nevaluate the security and tolerability in endostatin/recombined Endostatin in alliance with neoadjuvant chemotherapy and Concurrent chemo-radio therapy to treat the local advanced nasopharyngeal darcinoma.", 
            "measure": "main objective", 
            "safety_issue": "Yes", 
            "time_frame": "at the end of the Radiation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689558"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cancer Hospital of Guizhou Province", 
            "investigator_full_name": "Jin Feng", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "source": "Cancer Hospital of Guizhou Province", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jin Feng", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}